
Outlook Therapeutics, Inc. (NASDAQ:OTLK) stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.
Outlook Therapeutics traded lower, with a session volume of 26.41 million compared to the average volume of 1.51 million as per data from Benzinga Pro.